AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33884701 — intervention group
Group type: COMPARATOR
Intervention: Viscoelastic foam mattress
Number of subjects: 70
Study 33837158 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training with sleep hygiene (SH), n = 6
Number of subjects: 13
Study 33837158 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene alone, n = 7
Number of subjects: 13
Study 34968573 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic paravaginal repair and sacrocolpopexy
Number of subjects: 43
Study 34658006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab plus usual care (including corticosteroids at 1 mg/kg/day for at least 3 days)
Number of subjects: 201
Study 34658006 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (including corticosteroids at 1 mg/kg/day for at least 3 days)
Number of subjects: 201
Study 33070698 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise session
Number of subjects: 23
Study 33070698 — intervention group
Group type: COMPARATOR
Intervention: Control group (40-minute rest period)
Number of subjects: 23
Study 33395974 — intervention group
Group type: EXPERIMENTAL
Intervention: rtfMRI neurofeedback (NF) targeting the left lateral prefrontal cortex (lPFC)
Number of subjects: 41
Study 33395974 — intervention group
Group type: COMPARATOR
Intervention: Cognitive reappraisal without feedback (NoNF)
Number of subjects: 41
Study 35122086 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Frailty Phenotype (PFP)
Number of subjects: 2144
Study 35122086 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARE-Frailty Instrument (SHARE-FI)
Number of subjects: 2144
Study 35122086 — intervention group
Group type: EXPERIMENTAL
Intervention: SOF-Frailty Index (SOF-FI)
Number of subjects: 2144
Study 35122086 — intervention group
Group type: EXPERIMENTAL
Intervention: Country-specific prevalence
Number of subjects: 2144
Study 35122086 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with frailty
Number of subjects: 2144
Study 32239753 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling, holding and breastfeeding
Number of subjects: 160
Study 32239753 — intervention group
Group type: COMPARATOR
Intervention: Swaddling
Number of subjects: 160
Study 32239753 — intervention group
Group type: COMPARATOR
Intervention: Swaddling and holding
Number of subjects: 160
Study 32239753 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 160
Study 32815644 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Buddies™
Number of subjects: 687
Study 32815644 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 687
Study 32815644 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Buddies™ (boys subgroup)
Number of subjects: 687
Study 32815644 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Buddies™ (urban subgroup)
Number of subjects: 687
Study 35557479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg three times a day
Number of subjects: 30
Study 35557479 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen 1 mg twice a day
Number of subjects: 30
Study 33229940 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi DCB
Number of subjects: 216
Study 33229940 — intervention group
Group type: COMPARATOR
Intervention: SeQuent Please DCB
Number of subjects: 216
Study 33380323 — intervention group
Group type: EXPERIMENTAL
Intervention: 45° Trendelenburg position during RALP
Number of subjects: 80
Study 33380323 — intervention group
Group type: COMPARATOR
Intervention: Control group (RAPN)
Number of subjects: 80
Study 35521027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist education
Number of subjects: 43
Study 35521027 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 43
Study 35521027 — intervention group
Group type: COMPARATOR
Intervention: Text messages
Number of subjects: 43
Study 35521027 — intervention group
Group type: COMPARATOR
Intervention: Phone calls
Number of subjects: 43
Study 35521027 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (pharmacist and video education)
Number of subjects: 43
Study 34253208 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with paclitaxel plus cisplatin for two cycles followed by radical hysterectomy and bilateral adnexectomy
Number of subjects: 68
Study 34253208 — intervention group
Group type: COMPARATOR
Intervention: Radical hysterectomy and bilateral adnexectomy (control group)
Number of subjects: 68
Study 34253208 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with radical surgery
Number of subjects: 68
Study 32188988 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (1000 mg/day and 5 mg/day respectively)
Number of subjects: 70
Study 32188988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32188988 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 70
Study 36208817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.4 mg nicotine/g tobacco
Number of subjects: 753
Study 36208817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 2.4 mg nicotine/g tobacco
Number of subjects: 753
Study 36208817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 15.8 mg nicotine/g tobacco
Number of subjects: 753
Study 36208817 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 753
Study 34981483 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg per 12 hours)
Number of subjects: 80
Study 37133765 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy–Bladder Cancer (FACT-BL)
Number of subjects: 100
Study 32951013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin infusion at a mean dose of 0.3 ± 0.2 mU/kg/min
Number of subjects: 6
Study 32460575 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetry Span Task (working memory)
Number of subjects: 1060
Study 32460575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued Go/No-Go task (response inhibition)
Number of subjects: 1060
Study 34780705 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (0.5 mL injection administered on day 1, month 2, and month 6)
Number of subjects: 1803
Study 34780705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1803
Study 33706033 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM-ICU assessments twice daily for 5 days
Number of subjects: 788
Study 33706033 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM-ICU assessments twice daily for 4 days
Number of subjects: 788
Study 33706033 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM-ICU assessments twice daily for 3 days
Number of subjects: 788
Study 33706033 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning assessments
Number of subjects: 788
Study 33308683 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequently-exercising roommates
Number of subjects: 0
Study 33308683 — intervention group
Group type: COMPARATOR
Intervention: Non-frequently-exercising roommates
Number of subjects: 0
Study 32654517 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic changes in the right atrial appendage
Number of subjects: 239
Study 32654517 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP, hs-cTnT, CRP, oxidative stress biomarkers
Number of subjects: 239
Study 32654517 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial interstitial fibrosis, cardiomyocyte myocytolysis, cardiomyocyte diameter, glycogen score, Cx43 distribution
Number of subjects: 239
Study 35039313 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise and self-management programme (12-week programme)
Number of subjects: 112
Study 35039313 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no exercise programme)
Number of subjects: 112
Study 33222472 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (40 Gy in 15 fractions) concomitantly with temozolomide (TMZ) followed by adjuvant TMZ
Number of subjects: 0
Study 33222472 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study 32675772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg plus Rilpivirine 25 mg (early-switch group)
Number of subjects: 990
Study 32675772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg plus Rilpivirine 25 mg (late-switch group)
Number of subjects: 990
Study 32675772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus Rilpivirine (both groups)
Number of subjects: 990
Study 32675772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus Rilpivirine (early-switch group)
Number of subjects: 990
Study 32675772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus Rilpivirine (late-switch group)
Number of subjects: 990
Study 32675772 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants taking Tenofovir disoproxil fumarate pre-switch
Number of subjects: 990
Study 32675772 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants taking Dolutegravir plus Rilpivirine
Number of subjects: 990
Study 34392403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolic extract of propolis type-3 3% (EEP)
Number of subjects: 10
Study 34392403 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% (CHX)
Number of subjects: 10
Study 34392403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 33693741 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-Oligosaccharides (GOS) with iron fortified maize porridge (5 mg iron as FeFum + NaFeEDTA)
Number of subjects: 23
Study 33693741 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-Oligosaccharides (GOS) with iron fortified maize porridge (5 mg iron as FeSO4)
Number of subjects: 23
Study 33693741 — intervention group
Group type: COMPARATOR
Intervention: Iron fortified maize porridge (5 mg iron as FeFum + NaFeEDTA) without GOS
Number of subjects: 23
Study 33693741 — intervention group
Group type: COMPARATOR
Intervention: Iron fortified maize porridge (5 mg iron as FeSO4) without GOS
Number of subjects: 23
Study 32757651 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater PARP activity
Number of subjects: 3149
Study 32757651 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted elevation in PARP activity
Number of subjects: 3149
Study 35174415 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency stimulation (HF)
Number of subjects: 29
Study 35174415 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 29
Study 34304674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (1.0 mg/kg intravenously weekly)
Number of subjects: 0
Study 34304674 — intervention group
Group type: COMPARATOR
Intervention: Vorinostat (400 mg orally daily)
Number of subjects: 0
Study 35891246 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of CoronaVac® with 14 days between doses
Number of subjects: 2302
Study 35891246 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of CoronaVac® with 28 days between doses
Number of subjects: 2302
Study 35891246 — intervention group
Group type: EXPERIMENTAL
Intervention: Both schedules of CoronaVac®
Number of subjects: 2302
Study 32891160 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30-grams-dose once daily for four weeks
Number of subjects: 110
Study 32891160 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA)
Number of subjects: 110
Study 32891160 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pectin powder 1-gram-dose once daily for four weeks)
Number of subjects: 110
Study 33952313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health specialist video consultations
Number of subjects: 320
Study 33952313 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual by the GP
Number of subjects: 320
Study 32592986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 527
Study 32592986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 32592986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib (post hoc analysis)
Number of subjects: 527
Study 32592986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (post hoc analysis)
Number of subjects: 527
Study 35363632 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulation teaching process (n = 50)
Number of subjects: 100
Study 35363632 — intervention group
Group type: COMPARATOR
Intervention: Traditional workshop (control group, n = 50)
Number of subjects: 100
Study 33619667 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-Sustaining Treatment (LST) for severe disability scenario
Number of subjects: 1588
Study 33619667 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-Sustaining Treatment (LST) for vegetative state scenario
Number of subjects: 1588
Study 33619667 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for LST selection in severe disability scenario
Number of subjects: 1588
Study 33619667 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for LST selection in vegetative state scenario
Number of subjects: 1588
Study 35624520 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, virtual exercise intervention (telehealth exercise) consisting of two online group exercise sessions per week for 10 weeks, each session lasting 30 minutes and including aerobic and resistance exercise at moderate intensity.
Number of subjects: 20
Study 35624520 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, virtual exercise intervention (telehealth exercise)
Number of subjects: 20
Study 32907638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab plus Standard of Care
Number of subjects: 30
Study 32907638 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 30
Study 35927757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and synbiotic
Number of subjects: 88
Study 35927757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D placebo and synbiotic
Number of subjects: 88
Study 35927757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and synbiotic placebo
Number of subjects: 88
Study 35927757 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D placebo and synbiotic placebo
Number of subjects: 88
Study 33713756 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal nonopioid analgesic protocol
Number of subjects: 61
Study 33713756 — intervention group
Group type: COMPARATOR
Intervention: Standard opioid regimen
Number of subjects: 61
Study 33047918 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (M-TURP)
Number of subjects: 84
Study 33047918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar plasmakinetic transurethral resection of the prostate (PK-TURP)
Number of subjects: 84
Study 32144926 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-nine-needle therapy
Number of subjects: 150
Study 32144926 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture control
Number of subjects: 150
Study 32144926 — intervention group
Group type: COMPARATOR
Intervention: Western medicine control (epiperisone hydrochloride and fluoguili hydrochloride)
Number of subjects: 150
Study 34507355 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNα)
Number of subjects: 202
Study 34507355 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 202
Study 34507355 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 202
Study 33376120 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week interval oral health intervention
Number of subjects: 0
Study 33376120 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week interval oral health intervention
Number of subjects: 0
Study 33376120 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35232793 — intervention group
Group type: EXPERIMENTAL
Intervention: US branded packs without GWLs
Number of subjects: 287
Study 35232793 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐branded packs without GWLs (Blank)
Number of subjects: 287
Study 35232793 — intervention group
Group type: EXPERIMENTAL
Intervention: rotating non‐branded packs with GWLs (gangrene; throat cancer; neonatal baby)
Number of subjects: 287
Study 35232793 — intervention group
Group type: EXPERIMENTAL
Intervention: gangrene‐GWL pack
Number of subjects: 287
Study 35232793 — intervention group
Group type: EXPERIMENTAL
Intervention: Blank pack
Number of subjects: 287
Study 35232793 — intervention group
Group type: EXPERIMENTAL
Intervention: GWLs (blindness, teeth) not used in trial
Number of subjects: 287
Study 34454817 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting, best medical treatment (BMT) and exercise advice (stent group)
Number of subjects: 100
Study 34454817 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) and exercise advice alone (control group)
Number of subjects: 100
Study 32506563 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-session STAIR
Number of subjects: 26
Study 32506563 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 26
Study 36384735 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-modal palliative care intervention
Number of subjects: 240
Study 36384735 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 240
Study 33716036 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cystoscopy (arm B)
Number of subjects: 82
Study 33716036 — intervention group
Group type: COMPARATOR
Intervention: Standard cystoscopy (arm A)
Number of subjects: 82
Study 33941629 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 120
Study 33941629 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (upper limb immobilisation in long arm cast for 4 weeks)
Number of subjects: 120
Study 32447859 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture needle inserted vertically into EX-HN7 region
Number of subjects: 28
Study 32447859 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture needle inserted obliquely upward along the inferior orbital wall
Number of subjects: 28
Study 32447859 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture needle inserted inferiorly along the orbital inferior wall
Number of subjects: 28
Study 32447859 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended insertion depth for acupuncture needle
Number of subjects: 28
Study 36251300 — intervention group
Group type: EXPERIMENTAL
Intervention: Donanemab
Number of subjects: 272
Study 36251300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 34282575 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women (BMI ≥30 kg/m²)
Number of subjects: 465
Study 34282575 — intervention group
Group type: COMPARATOR
Intervention: Nonobese women (BMI <30 kg/m²)
Number of subjects: 465
Study 34338389 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing buprenorphine-naloxone (BUP-NX) dose in response to opioid use
Number of subjects: 270
Study 34338389 — intervention group
Group type: COMPARATOR
Intervention: Constant buprenorphine-naloxone (BUP-NX) dose after week 2
Number of subjects: 270
Study 32436633 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAT (1 hour of light exercise in a heat chamber, 5 times a week for 5 weeks)
Number of subjects: 23
Study 32436633 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAT
Number of subjects: 23
Study 32436633 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 23
Study 35614586 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromobilisation along with conservative treatment (ultrasound therapy, wrist splinting, tendon-gliding exercises)
Number of subjects: 66
Study 35614586 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (ultrasound therapy, wrist splinting, tendon-gliding exercises)
Number of subjects: 66
Study 34948565 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen adduction exercise (CA) for 8 weeks
Number of subjects: 12
Study 34948565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 32517847 — intervention group
Group type: EXPERIMENTAL
Intervention: DBV712 250 µg
Number of subjects: 356
Study 32517847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 35164720 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSRT-CR (Interpersonal and Social Rhythm Therapy with Cognitive Remediation)
Number of subjects: 100
Study 35164720 — intervention group
Group type: COMPARATOR
Intervention: IPSRT (Interpersonal and Social Rhythm Therapy) alone
Number of subjects: 100
Study 35164720 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSRT-CR
Number of subjects: 100
Study 35164720 — intervention group
Group type: COMPARATOR
Intervention: IPSRT
Number of subjects: 100
Study 34109646 — intervention group
Group type: EXPERIMENTAL
Intervention: LET's CONNECT (LC)
Number of subjects: 218
Study 34109646 — intervention group
Group type: COMPARATOR
Intervention: Control group (community resource information)
Number of subjects: 218
Study 32251146 — intervention group
Group type: EXPERIMENTAL
Intervention: Drilling energy
Number of subjects: 10
Study 32251146 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum screw compression
Number of subjects: 10
Study 34848180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular depot medroxyprogesterone acetate (DMPA‐IM)
Number of subjects: 829
Study 34848180 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 829
Study 34848180 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (copper‐IUD)
Number of subjects: 829
Study 34848180 — intervention group
Group type: COMPARATOR
Intervention: Randomized contraceptive preferences
Number of subjects: 829
Study 33185928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed/cisplatin (Pem/Cis)
Number of subjects: 389
Study 33185928 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine/cisplatin (Vnr/Cis)
Number of subjects: 389
Study 35818122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm (8 phone sessions + 8 weeks of nicotine patches)
Number of subjects: 818